<DOC>
	<DOCNO>NCT00971243</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy MP-513 combination Metformin patient type 2 diabetes 24 week administration evaluate safety efficacy MP-513 combination Metformin extension treatment 52 week .</brief_summary>
	<brief_title>Efficacy Safety MP-513 Combination With Metformin Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Patients age ≧ 18 year old . Patients whose HbA1c ≧ 7.0 % ＜ 10.0 % . Patients whose BMI ≧ 20.0 ≦40.0 ㎏/㎡ . Patients take metformin monotherapy least 56 consecutive day screen visit . Patients type 1 diabetes secondary form diabetes . Patients heart failure symptom . Patients serious diabetic complication . Patients severe hepatic disorder severe renal disorder . Patients excessive alcohol addict . Patients pregnant , lactate probably pregnant patient patient agree contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Insulin resistance</keyword>
</DOC>